Novo Nordisk A/S Common Stock · Transaction Mar 30, 2026 · Filed Jul 21, 2026 · $15,001 to $50,000
OMX NORDIC EXCHANGE COPENHAGEN A/S · NVO
+0.27% · +$0.1200 · Vol Not reported
Pre-market · updated 06:42:30 ET
Novo Nordisk A/S
Pharmaceuticals
$45.00
Veridion Score
Refresh
Score snapshot refresh in progress
Veridion Score History · 90D
Score not reportedVeridion does not publish a score-history trend for NVO until the ticker has a real scored snapshot. No trend is implied for this page.Review methodology
AI Analysis
SovereignWhy is NVO moving today?
Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About Novo Nordisk A/S
PharmaceuticalsListed since
1981
Employees
70K
Country
DK
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care segment. Novo also has a rare disease segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Key statistics
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Open
$44.88
Last session
Day high
$44.88
Last session
Day low
$44.88
Last session
Previous close
$44.88
52W high
$63.98
-29.67% from high
52W low
$35.29
34% of range
Market cap
$201.1B
P/E
11.40×
EPS
$26.18
Beta
0.15
Shares out
4.4B
Avg volume
11.7M
VWAP
$44.88
Last session
Price history computed in-house
1W
-4.60%
1M
-10.57%
3M
-0.16%
1Y
-16.28%
YTD
-11.56%
SMA 50 $47.25 · below
SMA 200 $46.49 · below
52W position 34%
NVO overview
Related filings and maps
Public disclosures
Congress activity in NVO
Official filing ↗
Ro KhannaBuy
NVO Common Stock · Transaction Mar 13, 2026 · Filed Apr 7, 2026 · Amount pending receipt enrichment
Ro KhannaBuy
NVO Common Stock · Transaction Feb 13, 2026 · Filed Mar 9, 2026 · Amount pending receipt enrichment
Novo Nordisk A/S Common Stock · Transaction Oct 31, 2025 · Filed Nov 21, 2025 · $1,001 to $15,000
Novo Nordisk A/S Common Stock · Transaction Oct 30, 2025 · Filed Nov 21, 2025 · $1,001 to $15,000
Federal contracts
NVO contract awards, year to date.
Public federal awards linked to this ticker.
Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for NVO in this window.
Lobbying spend
NVO lobbying filings, year to date.
Registered lobbying filings matched to Novo Nordisk A/S.
Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for NVO in this window.
Analyst ratings
Sovereign unlock shows live analyst consensus for NVO.
Options
Sovereign unlock shows live options positioning for NVO.